Logo

Tempus: Christopher Mason

Oct 02, 2020

Christopher Mason is planning to take a leave of absence from his post as associate professor in the Department of Physiology and Biophysics at Weill Cornell Medicine to work on COVID-19 testing, including at Tempus, Biotia, and labs in Wisconsin and New York City. Chicago-based Tempus said in June that Mason has joined the firm as VP of emerging genome technology. He holds a PhD in genetics from Yale University and a dual BS degree in genetics and biochemistry from the University of Wisconsin-Madison.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.